Memphasys (ASX:MEM) said the publication of a study in the "Antioxidants" journal reinforces the commercial potential as well as the scientific credibility of its RoXsta platform to identify oxidative stress in human and animal samples, according to a Thursday Australian bourse filing.
RoXsta is a proprietary antioxidant diagnostic platform for identifying oxidative stress-related deficiencies, and the study supports its ability to diagnose oxidative stress through analysis of biological fluids, the filing added.
The RoXsta system has potential for male infertility treatments as well as disease management in conditions such as neurodegenerative diseases, cardiovascular disorders, and cancer, the filing said.
It is also exploring its potential for the optimization of livestock productivity by mitigating oxidative stress.
Oxidative stress is linked to infertility, cardiovascular disease, neurodegenerative disorders, cancer, and other conditions, the filing said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。